Double maintains 2 strategies that include AGIO - Agios Pharmaceuticals, Inc.
Current Value
$28.371 Year Return
Current Value
$28.371 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NEE | 0.01% | $153.47B | -2.43% | 2.84% |
REAL | -0.08% | $596.01M | +21.15% | 0.00% |
REYN | 0.10% | $4.88B | -20.08% | 4.00% |
CARV | -0.14% | $7.41M | -22.87% | 0.00% |
UTZ | -0.15% | $1.11B | -29.27% | 1.86% |
EDU | -0.21% | $7.99B | -41.11% | 0.00% |
SBAC | 0.24% | $24.62B | +12.92% | 1.76% |
BVN | -0.33% | $3.68B | -15.25% | 0.00% |
CYCN | -0.34% | $9.37M | +2.39% | 0.00% |
IMNN | 0.35% | $8.21M | -59.89% | 0.00% |
SHLS | 0.43% | $765.66M | -33.04% | 0.00% |
AGRO | -0.44% | $891.94M | -18.01% | 3.91% |
FE | 0.48% | $24.49B | +5.52% | 4.06% |
PRPO | 0.48% | $10.84M | +15.14% | 0.00% |
CLX | 0.53% | $16.64B | -1.45% | 3.61% |
SAIC | -0.56% | $5.75B | -10.80% | 1.22% |
EHAB | 0.58% | $544.86M | +28.86% | 0.00% |
ES | -0.59% | $22.92B | +1.50% | 5.85% |
PRT | 0.59% | $46.96M | +0.80% | 11.43% |
AIFU | -0.62% | $9.85M | -95.03% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
INSM | 46.87% | $12.24B | +167.81% | 0.00% |
CRNX | 43.79% | $2.92B | -39.88% | 0.00% |
ARCT | 43.06% | $315.68M | -61.84% | 0.00% |
LGND | 41.30% | $2.00B | +21.70% | 0.00% |
COHR | 41.05% | $12.25B | +35.13% | 0.00% |
ROIV | 40.93% | $7.68B | -5.70% | 0.00% |
RVMD | 40.90% | $7.35B | +1.15% | 0.00% |
KYMR | 40.78% | $1.95B | -15.67% | 0.00% |
DNLI | 40.72% | $2.06B | -30.04% | 0.00% |
IDYA | 40.56% | $1.52B | -58.32% | 0.00% |
ZYME | 40.41% | $810.02M | +22.92% | 0.00% |
TWST | 39.51% | $1.80B | -35.27% | 0.00% |
HZO | 39.05% | $491.53M | -15.72% | 0.00% |
VTYX | 38.68% | $86.11M | -75.70% | 0.00% |
KRYS | 38.67% | $3.77B | -20.42% | 0.00% |
CRSP | 38.61% | $3.14B | -34.78% | 0.00% |
VRDN | 37.92% | $1.03B | -13.74% | 0.00% |
ARWR | 37.91% | $2.12B | -38.64% | 0.00% |
XENE | 37.88% | $2.27B | -26.70% | 0.00% |
IONS | 37.32% | $5.25B | -12.31% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MOMO | -18.58% | $768.25M | +8.00% | 0.00% |
HSY | -11.97% | $33.16B | -21.37% | 3.44% |
CME | -10.98% | $98.74B | +28.80% | 3.84% |
MKTX | -10.65% | $8.01B | -1.42% | 1.39% |
PAC | -10.45% | $9.83B | +16.49% | 0.00% |
VSTA | -10.38% | $326.82M | +11.64% | 0.00% |
FMTO | -10.06% | $45.74M | -99.96% | 0.00% |
ZCMD | -10.00% | $32.45M | -11.38% | 0.00% |
JKHY | -9.38% | $13.15B | +6.64% | 1.23% |
GIS | -9.24% | $29.79B | -23.81% | 4.42% |
K | -8.96% | $28.49B | +32.17% | 2.77% |
CIG.C | -8.88% | $2.45B | +9.77% | 0.00% |
CNC | -8.73% | $29.89B | -22.14% | 0.00% |
CBOE | -8.73% | $22.95B | +20.67% | 1.12% |
ED | -8.61% | $36.75B | +5.26% | 3.28% |
VZ | -7.93% | $183.32B | +8.02% | 6.21% |
BGS | -7.25% | $355.90M | -53.30% | 17.00% |
CELH | -6.98% | $10.06B | -57.82% | 0.00% |
LITB | -6.87% | $21.28M | -72.45% | 0.00% |
ARRY | -6.55% | $1.29B | -25.57% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 53.91% | $4.85B | 0.35% |
CPRJ | 46.28% | $48.43M | 0.69% |
BTC | 45.27% | $4.48B | 0.15% |
QQA | 45.16% | $225.66M | 0.29% |
IBB | 44.56% | $5.22B | 0.45% |
PBE | 43.52% | $214.12M | 0.58% |
ARKG | 42.85% | $944.78M | 0.75% |
XPH | 42.69% | $136.58M | 0.35% |
IWO | 42.28% | $11.36B | 0.24% |
GNOM | 42.13% | $40.65M | 0.5% |
RSPA | 41.70% | $319.03M | 0.29% |
PTH | 41.35% | $96.56M | 0.6% |
FBT | 41.27% | $994.71M | 0.56% |
IWC | 40.45% | $766.88M | 0.6% |
ARKK | 40.21% | $5.95B | 0.75% |
ISCG | 39.92% | $645.00M | 0.06% |
VTWO | 39.50% | $12.07B | 0.07% |
VBK | 39.41% | $18.33B | 0.07% |
IWM | 39.31% | $63.95B | 0.19% |
PINK | 39.28% | $131.52M | 0.5% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BSMW | -0.05% | $102.62M | 0.18% |
BWX | 0.10% | $1.41B | 0.35% |
XONE | 0.17% | $603.24M | 0.03% |
CNBS | 0.23% | $69.42M | 0.77% |
JMST | -0.33% | $3.65B | 0.18% |
SHV | -0.36% | $20.94B | 0.15% |
CLIP | -0.38% | $1.50B | 0.07% |
OILK | 0.41% | $63.21M | 0.69% |
XBIL | 0.44% | $782.40M | 0.15% |
MSOS | 0.45% | $354.62M | 0.77% |
UDN | 0.45% | $137.74M | 0.78% |
USDU | 0.46% | $173.44M | 0.5% |
IBTG | -0.54% | $1.88B | 0.07% |
WEAT | -0.57% | $115.83M | 0.28% |
KBA | -0.60% | $175.37M | 0.56% |
USL | -0.61% | $41.76M | 0.85% |
UNG | 0.77% | $371.83M | 1.06% |
KRBN | 0.82% | $160.09M | 0.85% |
VGSH | -0.83% | $22.38B | 0.03% |
FXE | 0.86% | $525.40M | 0.4% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -30.75% | $361.41M | 1.43% |
VIXY | -30.43% | $109.64M | 0.85% |
TAIL | -28.05% | $140.49M | 0.59% |
IVOL | -8.91% | $353.94M | 1.02% |
TPMN | -8.28% | $31.54M | 0.65% |
KCCA | -8.08% | $97.18M | 0.87% |
XHLF | -7.79% | $1.46B | 0.03% |
GBIL | -7.54% | $6.17B | 0.12% |
BIL | -6.35% | $45.95B | 0.1356% |
FXY | -5.98% | $838.61M | 0.4% |
TFLO | -5.31% | $7.06B | 0.15% |
FTSD | -4.52% | $212.46M | 0.25% |
TBIL | -4.45% | $5.76B | 0.15% |
UGA | -4.39% | $73.47M | 0.97% |
BILZ | -4.33% | $876.85M | 0.14% |
SCHO | -4.18% | $10.87B | 0.03% |
SHYM | -3.71% | $322.93M | 0.35% |
BILS | -3.59% | $3.96B | 0.1356% |
SPTS | -3.56% | $5.76B | 0.03% |
TBLL | -2.86% | $2.46B | 0.08% |
Yahoo
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on the company’s PK activators, mitapivat and tebapivat, will be featured in oral and poster presentations during the 30th European Hematology Association (EHA) Congress (EHA 2025) in Milan, Italy, June 12-15, 2025. “The clinical results and scientific insights being
Yahoo
We didn't see Agios Pharmaceuticals, Inc.'s ( NASDAQ:AGIO ) stock surge when it reported robust earnings recently. We...
Yahoo
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 8:00 am ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A re
Yahoo
AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.
Yahoo
CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 8:00 am PT/11:00 am ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A
Yahoo
Agios Pharmaceuticals Inc (AGIO) reports a 6% revenue increase and outlines promising pipeline developments, despite facing revenue and expense challenges.